Streetbeat News

AVTE

Aerovate Therapeutics, Inc.

Industry

Biotechnology

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Open

2.58

Mkt cap

75M

Volume

18K

High

2.62

P/E Ratio

-0.87

52-wk high

32.41

Low

2.55

Div yield

N/A

52-wk low

1.25

Monteverde & Associates PC is investigating the merger between Aerovate Therapeutics, Inc. and Jade Biosciences. Aerovate shareholders will own 1.6% of the new entity, while Jade shareholders will own 98.4%.

Portfolio Pulse from

November 06, 2024 | 12:00 am

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

Aerovate Therapeutics shares rose following the announcement of an all-stock merger with Jade Biosciences, aiming to advance Jade's biologics portfolio.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:50 pm

The article highlights significant pre-market movements in healthcare stocks on Thursday. Notable gainers include Autonomix Medical, Tenon Medical, and Aerovate Therapeutics, while Matinas BioPharma and Equillium are among the biggest losers. Several companies reported Q3 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:10 pm

Several healthcare stocks experienced significant price movements in Thursday's pre-market session. Notable gainers include Autonomix Medical, Tenon Medical, and Alphatec Holdings, while Matinas BioPharma and Equillium saw substantial declines.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:09 pm

The trading halt status was updated at 7:25 AM ET, indicating a quotation resumption. This update is relevant for investors tracking trading activities and potential impacts on stock prices.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:25 am

Aerovate Therapeutics and Jade Biosciences have agreed to merge in an all-stock transaction, creating a company focused on Jade's biologics portfolio, including JADE-001 for IgA Nephropathy. The new entity will trade on Nasdaq under 'JBIO'.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:23 am

Trading for a certain asset has been halted as of 6:55:00 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:55 am

In Tuesday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Inspire Veterinary, CASI Pharmaceuticals, and Shuttle Pharmaceuticals, while Nuwellis, Puma Biotechnology, and Agape ATP were among the losers.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 8:31 pm

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced it will explore strategic alternatives, including potential acquisitions, mergers, or other transactions, following the halt of its Phase 3 clinical trial for Inhaled iMatinib Pulmonary Arterial Hypertension.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.